dc.contributor.author | Klampatsa, A | |
dc.contributor.author | Haas, AR | |
dc.contributor.author | Moon, EK | |
dc.contributor.author | Albelda, SM | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2022-09-02T08:13:01Z | |
dc.date.available | 2022-09-02T08:13:01Z | |
dc.date.issued | 2017-09-01 | |
dc.identifier | ARTN 115 | |
dc.identifier | cancers9090115 | |
dc.identifier.citation | Cancers, 2017, 9 (9), pp. E115 - | en_US |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5372 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.doi | 10.3390/cancers9090115 | |
dc.description.abstract | Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs are engineered receptors, stably or transiently transduced into T cells, that aim to enhance T cell effector function by recognizing and binding to a specific tumor-associated antigen. In this review, we provide a summary of CAR T cell preclinical studies and clinical trials for malignant pleural mesothelioma (MPM), a rare, locally invasive pleural cancer with poor prognosis. We list other attractive potential targets for CAR T cell therapy for MPM, and discuss augmentation strategies of CAR T cell therapy with other forms of immunotherapy in this disease. | |
dc.format | Electronic | |
dc.format.extent | E115 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartof | Cancers | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | adoptive cell transfer | |
dc.subject | chimeric antigen receptor T cells | |
dc.subject | immunotherapy | |
dc.subject | mesothelioma | |
dc.title | Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-08-30 | |
dc.date.updated | 2022-09-02T08:12:26Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.3390/cancers9090115 | en_US |
rioxxterms.licenseref.startdate | 2017-09-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/28862644 | |
pubs.issue | 9 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Thoracic Oncology Immunotherapy Group (TOIG) | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/cancers9090115 | |
pubs.volume | 9 | |
icr.researchteam | Thor Onco Immuno Group | en_US |
dc.contributor.icrauthor | Klampatsa, Astero | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-02. Deposit type is initial. No. of files: 1. Files: Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). .pdf | |